Oruka Therapeutics
ORKA
79.50
-0.68
-0.85%
Oruka Therapeutics
US · ORKA
#2003 by market cap
Listed 1970
79.50
-0.68
-0.85%
Live - 5344 symbols - heartbeat 77s ago
· 2026-10-08 06:50
Pre-market
78.50
-1.26%
After-hours
79.50
0.00%
- Market cap
- 5.26B
- P/E (TTM)i
- -38.97
- P/Bi
- 4.74
- EPSi
- -1.85
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on ORKA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | 21.41M |
| Research & development | -- | 100.64M |
| Operating profit | -- | -122.05M |
| Pretax profit | -- | -105.43M |
| Tax | -- | -- |
| Net profit | -- | -105.43M |
| Basic EPS | -- | -2 |
| Diluted EPS | -- | -1.85 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.16M | 4.34M | 5.12M | 6.79M | 7.29M | 6.85M |
| Research & development | 19.93M | 24.09M | 28.99M | 27.64M | 29.15M | 43.26M |
| Operating profit | -25.09M | -28.43M | -34.11M | -34.43M | -36.43M | -50.11M |
| Pretax profit | -21.00M | -24.57M | -30.28M | -29.58M | -31.82M | -41.21M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -21.00M | -24.57M | -30.28M | -29.58M | -31.82M | -41.21M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | -1 |
| Diluted EPS | -0.40 | -0.46 | -0.55 | -0.45 | -0.48 | -0.55 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 376.87M | 343.86M |
| Cash & ST investments | 375.65M | 337.04M |
| Inventory | -- | -- |
| Total assets | 396.02M | 488.62M |
| Total current liabilities | 13.04M | 15.37M |
| Short-term debt | 213.00K | 619.00K |
| Long-term debt | -- | -- |
| Total liabilities | 16,729,000.00 | 19,618,000.00 |
| Total equity | 379.29M | 469.00M |
| Retained earnings | -83.72M | -189.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 352.08M | 332.01M | 355.16M | 343.86M | 395.25M | 884.56M |
| Cash & ST investments | 349.09M | 328.41M | 349.16M | 337.04M | 388.83M | 873.56M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 377.11M | 357.42M | 509.25M | 488.62M | 504.48M | 1.14B |
| Total current liabilities | 11.72M | 12.11M | 20.97M | 15.37M | 16.63M | 22.97M |
| Short-term debt | 283.00K | 660.00K | 419.00K | 619.00K | 680.00K | 669.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 12,387,000.00 | 13,776,000.00 | 22,460,000.00 | 19,618,000.00 | 20,691,000.00 | 27,776,000.00 |
| Total equity | 364.73M | 343.64M | 486.79M | 469.00M | 483.79M | 1.11B |
| Retained earnings | -104.72M | -129.30M | -159.57M | -189.16M | -220.98M | -262.18M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -- | -88.21M |
| Depreciation & amortization | -- | 83.00K |
| Free cash flow | -- | -88.42M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | 671.00K |
| Ending cash balance | -- | 46.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -20.87M | -23.15M | -21.60M | -22.59M | -23.58M | -33.15M |
| Depreciation & amortization | 16.00K | 19.00K | 20.00K | 28.00K | 43.00K | 43.00K |
| Free cash flow | -20.88M | -23.18M | -21.70M | -22.66M | -23.65M | -33.15M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 109.00K | 562.00K | 40.60M | 4.37M |
| Ending cash balance | 83.57M | 65.40M | 91.25M | 46.94M | 49.52M | 268.47M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -24.86 |
| ROA %i | -- | -23.84 |
| ROIC %i | -- | -28.68 |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 28.89 | 22.37 |
| Quick ratioi | 28.80 | 21.92 |
| Debt / assetsi | 0.24 | 0.40 |
| LT debt / equityi | 0.20 | 0.28 |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -24.86 | -27.50 | -18.30 |
| ROA %i | -- | -- | -- | -23.84 | -26.37 | -17.76 |
| ROIC %i | -- | -- | -- | -28.68 | -31.45 | -21.28 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 30.03 | 27.42 | 16.94 | 22.37 | 23.76 | 38.51 |
| Quick ratioi | 29.78 | 27.12 | 16.65 | 21.92 | 23.38 | 38.03 |
| Debt / assetsi | 0.25 | 0.65 | 0.38 | 0.40 | 0.36 | 0.22 |
| LT debt / equityi | 0.18 | 0.49 | 0.31 | 0.28 | 0.23 | 0.17 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 06:50:07 · For reference only, not investment advice and not tailored to your situation.